רוקחות-פרמקולוגיה

Europe Approves Desloratadine Syrup And Rapidly Disintegrating Tablets For Seasonal Allergies In Adults And Children

KENILWORTH, NJ — April 25, 2002 — Schering-Plough Corporation today announced that the European Commission of the European Union (EU) has granted marketing authorization for a syrup formulation of the nonsedating antihistamine desloratadine as a once-daily treatment for seasonal allergies and the symptoms of chronic idiopathic urticaria (CIU) such as itching or hives for adults and children two years of age and older.

The commission also granted marketing authorization for desloratadine in a rapidly disintegrating tablet formulation (oral lyophilisate) for seasonal allergies and CIU in adults and children 12 years of age and older.

Commission approval of the centralized application for the syrup and rapidly disintegrating tablet formulations results in a single Marketing Authorization with unified labeling for each product that is immediately valid in all 15 EU-Member States as well as in Iceland and Norway. The commission's decision follows the recommendations for approval for the two formulations in December 2001 by the EU's Committee for Proprietary Medicinal Products (CPMP) of the European Agency for the Evaluation of Medicinal Products (EMEA).

לכתבה המלאה

0 תגובות

השאירו תגובה

רוצה להצטרף לדיון?
תרגישו חופשי לתרום!

כתיבת תגובה

מידע נוסף לעיונך

כתבות בנושאים דומים

© ‫ e-Med
 כל הזכויות שמורות

 

התכנים המוצגים באתר זה מיועדים לאנשי צוות רפואי בלבד

אם כבר נרשמת, יש להקליד את פרטי הזיהוי שלך
עדיין לא נרשמת? באפשרותך לבצע רישום כאן
להרשמה לאתר